PRP-HOM, SRBE, Laboratory of Radiopathology and Experimental Therapy, Radiological Protection and Human Health Division, Institute of Radiological Protection and Nuclear Safety, 92260 Fontenay-aux-Roses, France ; UMRS 938 Department of Hematology, Saint Antoine Hospital APHP and UPMC University, 75012 Paris, France.
PRP-HOM, SRBE, Laboratory of Radiopathology and Experimental Therapy, Radiological Protection and Human Health Division, Institute of Radiological Protection and Nuclear Safety, 92260 Fontenay-aux-Roses, France.
Stem Cells Int. 2014;2014:939275. doi: 10.1155/2014/939275. Epub 2014 Feb 11.
There is little information on the fate of infused mesenchymal stem cells (MSCs) and long-term side effects after irradiation exposure. We addressed these questions using human MSCs (hMSCs) intravenously infused to nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice submitted to total body irradiation (TBI) or local irradiation (abdominal or leg irradiation). The animals were sacrificed 3 to 120 days after irradiation and the quantitative and spatial distribution of hMSCs were studied by polymerase chain reaction (PCR). Following their infusion into nonirradiated animals, hMSCs homed to various tissues. Engraftment depended on the dose of irradiation and the area exposed. Total body irradiation induced an increased hMSC engraftment level compared to nonirradiated mice, while local irradiations increased hMSC engraftment locally in the area of irradiation. Long-term engraftment of systemically administered hMSCs in NOD/SCID mice increased significantly in response to tissue injuries produced by local or total body irradiation until 2 weeks then slowly decreased depending on organs and the configuration of irradiation. In all cases, no tissue abnormality or abnormal hMSCs proliferation was observed at 120 days after irradiation. This work supports the safe and efficient use of MSCs by injection as an alternative approach in the short- and long-term treatment of severe complications after radiotherapy for patients refractory to conventional treatments.
关于输注间充质干细胞(MSCs)的命运和照射暴露后的长期副作用的信息很少。我们使用静脉内输注给非肥胖糖尿病/严重联合免疫缺陷(NOD/SCID)小鼠的人 MSCs(hMSCs)来解决这些问题,这些小鼠接受了全身照射(TBI)或局部照射(腹部或腿部照射)。照射后 3 至 120 天处死动物,并通过聚合酶链反应(PCR)研究 hMSC 的定量和空间分布。在输注到未照射的动物后,hMSCs 归巢到各种组织。植入取决于照射剂量和暴露面积。与未照射的小鼠相比,全身照射诱导 hMSC 植入水平增加,而局部照射则在照射区域局部增加 hMSC 植入。局部或全身照射引起的组织损伤使系统给予的 hMSCs 在 NOD/SCID 小鼠中的长期植入显著增加,直到 2 周后,然后根据器官和照射方式缓慢减少。在所有情况下,照射后 120 天未观察到组织异常或异常 hMSC 增殖。这项工作支持通过注射将 MSC 作为对常规治疗无效的患者接受放射治疗后严重并发症的短期和长期治疗的替代方法的安全有效使用。